01—Abstract
Summary
Summary of the 10-Q filed July 24, 2024. Cited figures are marked; the original filing is the authoritative source.
Quest Diagnostics Inc. reported solid financial results for the second quarter and first half of 2024.
While net income attributable to Quest Diagnostics saw a slight decrease compared to the prior year periods, this was largely influenced by factors such as increased amortization, restructuring costs, and changes in the carrying value of strategic investments. However, the core Diagnostic Information Services (DIS) business demonstrated resilience, with net revenues growing by 2.8%a for the quarter and 2.3% for the half-year. This growth was primarily driven by an increase in base business volume and revenue per requisition, as the company continues to reduce its reliance on COVID-19 testing.
The company is actively pursuing strategic growth through acquisitions, having completed two acquisitions in the first half of 2024, and announced a significant agreement to acquire LifeLabs Inc. in Canada. Quest Diagnostics is also focused on internal efficiency improvements through its "Invigorate Program," aiming for 3%b annual cost savings. Despite a challenging operating environment with inflationary pressures and reimbursement challenges, the company maintained a strong liquidity position and reaffirmed its commitment to returning capital to shareholders through dividends and share repurchases, with a substantial amount still available under its repurchase authorization.
02—Key points
Key Highlights
- Total net revenues increased by 2.5% to $2.4 billion for the three months ended June 30, 2024, and by 2.0% to $4.8 billion for the six months ended June 30, 2024, compared to the prior year periods.
- The core Diagnostic Information Services (DIS) business revenue grew by 2.8% to $2.3 billion for the three months and 2.3% to $4.6 billion for the six months, driven by an increase in base business volume and revenue per requisition.
- Acquisitions continue to be a growth driver, with two acquisitions completed in the first half of 2024 and a significant pending acquisition of LifeLabs Inc. for approximately C$1.35 billion announced in July 2024.
- Net income attributable to Quest Diagnostics decreased by 2.4% to $229 million for the quarter and by 3.1% to $423 million for the half-year, impacted by restructuring charges, amortization, and investment valuation changes.
- Diluted earnings per share were $2.03 for the quarter and $3.75 for the half-year, slightly down from $2.05 and $3.83 in the prior year periods, respectively.
- The company is actively managing costs and driving efficiencies through its "Invigorate Program," which aims for 3% annual cost savings and productivity improvements.
- Quest Diagnostics maintained a strong liquidity position with $271 million in cash and cash equivalents as of June 30, 2024, and significant borrowing capacity available under its credit facilities.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2024, Quest Diagnostics Inc kept $0.10.
- Revenue$2.40B100.0%
- Cost of revenue−$1.59B66.5%
- Gross profit$804.0M33.5%
- Operating costs−$449.0M18.7%
- Operating income$355.0M14.8%
- Interest, other & tax−$126.0M5.3%
- Net income$229.0M9.6%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2024filed July 24, 2024Financial Statements
Q2 FY2024 against Q2 FY2023
| Line item | Q2 FY2024Q2 FY2023 | Change |
|---|---|---|
| Revenue | $2.40B$2.34B | +2.5% |
| Cost of Revenue | $1.59B$1.55B | +3.0% |
| Gross Profit | $804.00M$792.00M | +1.5% |
| SG&A Expenses | $416.00M$416.00M | 0.0% |
| Operating Expenses | $2.04B$1.99B | +2.6% |
| Operating Income | $355.00M$348.00M | +2.0% |
| Interest Expense | $47.00M$39.00M | +20.5% |
| Net Income | $229.00M$235.00M | −2.6% |
| EPS (Basic) | $2.05$2.08 | −1.4% |
| EPS (Diluted) | $2.03$2.05 | −1.0% |
| Shares Outstanding (Basic) | 111.00M112.00M | −0.9% |
| Shares Outstanding (Diluted) | 112.00M114.00M | −1.8% |
05—Questions
Frequently Asked Questions
What are the main drivers of revenue growth for Quest Diagnostics?
Revenue growth is primarily driven by the core Diagnostic Information Services (DIS) business. Key factors include an increase in base business testing volume, a favorable change in revenue per requisition due to more tests per requisition and favorable test mix, and contributions from recent acquisitions. The company is also focused on offsetting declines in COVID-19 testing revenue.
How is the company managing its costs and improving efficiency?
Quest Diagnostics is implementing a multi-year "Invigorate Program" designed to drive cost savings and productivity improvements across its operations. This program leverages automation and artificial intelligence, and focuses on areas like patient services, logistics, and procurement. The program aims to achieve 3% annual cost savings to mitigate inflationary pressures and reimbursement challenges.
What is the company's strategy for future growth?
The company's growth strategy includes both organic expansion of its core DIS business and strategic acquisitions. Quest Diagnostics has completed several acquisitions in the past year and recently announced a significant agreement to acquire LifeLabs Inc. in Canada, which is expected to close by the end of 2024. These acquisitions are aimed at expanding the company's geographic reach and service offerings.
What is the impact of the FDA's new regulations on laboratory-developed tests (LDTs)?
The FDA recently published a final rule broadening the definition of medical devices to include diagnostic tests and regulating laboratories that develop them. This rule initiates a four-year compliance period. Quest Diagnostics is evaluating the rule and working towards compliance. Legal challenges exist, and the ultimate impact on the industry, including potential new competitors and competition forms, is still uncertain.
06—Continue